Emerging role of HMGB1 in fibrotic diseases

Journal of Cellular and Molecular Medicine

Volumn 18, Issue 12, 2014, Pages 2331-2339

  Li, Liu Cheng ^a   Gao, Jian ^a   Li, Jun ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Cystic fibrosis; High mobility group box 1; Liver fibrosis; Myocardial fibrosis; Pulmonary fibrosis; Renal fibrosis

Indexed keywords

ANTIBODY; HIGH MOBILITY GROUP B1 PROTEIN;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CYSTIC FIBROSIS; DRUG EFFECTS; HUMAN; IMMUNOLOGY; LIVER CIRRHOSIS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES; CYSTIC FIBROSIS; HMGB1 PROTEIN; HUMANS; LIVER CIRRHOSIS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; PULMONARY FIBROSIS; SIGNAL TRANSDUCTION;

EID: 84911379523     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12419     Document Type: Article

References (79)

1. Friedman SL, Sheppard D, Duffield JS, et al. Therapy for fibrotic diseases: nearing the starting line. Sci Transl Med. 2013; 5: 167sr1.
2. Bonner JC. Regulation of PDGF and its receptors in fibrotic diseases. Cytokine Growth Factor Rev. 2004; 15: 255-73.
3. Wynn TA. Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases. J Clin Invest. 2007; 117: 524-9.
4. Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving autoimmune and inflammatory disease. Nat Rev Rheumatol. 2012; 8: 195-202.
5. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002; 418: 191-5.
6. van Zoelen MA, Yang H, Florquin S, et al. Role of toll-like receptors 2 and 4, and the receptor for advanced glycation end products in high-mobility group box 1-induced inflammation in vivo. Shock. 2009; 31: 280-4.
7. Yang H, Antoine DJ, Andersson U, et al. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol. 2013; 93: 865-73.
8. Andersson U, Tracey KJ. HMGB1 is a therapeutic target for sterile inflammation and infection. Annu Rev Immunol. 2011; 29: 139-62.
9. Furlani D, Donndorf P, Westien I, et al. HMGB-1 induces c-kit+ cell microvascular rolling and adhesion via both toll-like receptor-2 and toll-like receptor-4 of endothelial cells. J Cell Mol Med. 2012; 16: 1094-105.
10. Ulloa L, Batliwalla FM, Andersson U, et al. High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum. 2003; 48: 876-81.
11. Bustin M. Revised nomenclature for high mobility group (HMG) chromosomal proteins. Trends Biochem Sci. 2001; 26: 152-3.
12. Reeck GR, Isackson PJ, Teller DC. Domain structure in high molecular weight high mobility group nonhistone chromatin proteins. Nature. 1982; 300: 76-8.
13. Bustin M, Reeves R. High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol. 1996; 54: 35-100.
14. Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol. 2005; 5: 331-42.
15. Chen Y, Sun W, Gao R, et al. The role of high mobility group box chromosomal protein 1 in rheumatoid arthritis. Rheumatology 2013; 52: 1739-47.
16. Ulloa L, Messmer D. High-mobility group box 1 (HMGB1) protein: friend and foe. Cytokine Growth Factor Rev. 2006; 17: 189-201.
17. Li J, Kokkola R, Tabibzadeh S, et al. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med. 2003; 9: 37-45.
18. Ugrinova I, Zlateva S, Pashev IG, et al. Native HMGB1 protein inhibits repair of cisplatin-damaged nucleosomes in vitro. Int J Biochem Cell Biol. 2009; 41: 1556-62.
19. Mitkova E, Ugrinova I, Pashev IG, et al. The inhibitory effect of HMGB-1 protein on the repair of cisplatin-damaged DNA is accomplished through the acidic domain. Biochemistry. 2005; 44: 5893-8.
20. Banerjee S, Friggeri A, Liu G, et al. The C-terminal acidic tail is responsible for the inhibitory effects of HMGB1 on efferocytosis. J Leukoc Biol. 2010; 88: 973-9.
21. Park JS, Svetkauskaite D, He Q, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem. 2004; 279: 7370-7.
22. Ivanov S, Dragoi AM, Wang X, et al. A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood. 2007; 110: 1970-81.
23. Yu M, Wang H, Ding A, et al. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006; 26: 174-9.
24. Hori O, Brett J, Slattery T, et al. The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem. 1995; 270: 25752-61.
25. Hreggvidsdottir HS, Ostberg T, Wähämaa H, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol. 2009; 86: 655-62.
26. Schmidt AM, Stern DM. Receptor for age (RAGE) is a gene within the major histocompatibility class III region: implications for host response mechanisms in homeostasis and chronic disease. Front Biosci. 2001; 6: D1151-60.
27. Sparvero LJ, Asafu-Adjei D, Kang R, et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J Transl Med. 2009; 7: 17.
28. Kokkola R, Andersson A, Mullins G, et al. RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand J Immunol. 2005; 61: 1-9.
29. Yang H, Hreggvidsdottir HS, Palmblad K, et al. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci USA. 2010; 107: 11942-7.
30. Boonyaratanakornkit V, Melvin V, Prendergast P, et al. High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells. Mol Cell Biol. 1998; 18: 4471-87.
31. Melvin VS, Edwards DP. Coregulatory proteins in steroid hormone receptor action: the role of chromatin high mobility group proteins HMG-1 and -2. Steroids. 1999; 64: 576-86.
32. Ueda T, Yoshida M. HMGB proteins and transcriptional regulation. Biochim Biophys Acta. 2010; 1799: 114-8.
33. Jayaraman L, Moorthy NC, Murthy KG, et al. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes Dev. 1998; 12: 462-72.
34. Agresti A, Lupo R, Bianchi ME, et al. HMGB1 interacts differentially with members of the Rel family of transcription factors. Biochem Biophys Res Commun. 2003; 302: 421-6.
35. Verrijdt G, Haelens A, Schoenmakers E, et al. Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors. Biochem J. 2002; 361: 97-103.
36. Calogero S, Grassi F, Aguzzi A, et al. The lack of chromosomal protein Hmg1 does not disrupt cell growth but causes lethal hypoglycaemia in newborn mice. Nat Genet. 1999; 22: 276-80.
37. Messmer D, Yang H, Telusma G, et al. High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol. 2004; 173: 307-13.
38. Dumitriu IE, Baruah P, Valentinis B, et al. Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol. 2005; 174: 7506-15.
39. Mittal D, Saccheri F, Vénéreau E, et al. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. EMBO J. 2010; 29: 2242-52.
40. Ho YY, Lagares D, Tager AM, et al. Fibrosis-a lethal component of systemic sclerosis. Nat Rev Rheumatol. 2014; 10: 390-402.
41. Manetti M, Rosa I, Messerini L, et al. A loss of telocytes accompanies fibrosis of multiple organs in systemic sclerosis. J Cell Mol Med. 2014; 18: 253-62.
42. Manetti M, Guiducci S, Ruffo M, et al. Evidence for progressive reduction and loss of telocytes in the dermal cellular network of systemic sclerosis. J Cell Mol Med. 2013; 17: 482-96.
43. Ayer LM, Sénecal JL, Martin L, et al. Antibodies to high mobility group proteins in systemic sclerosis. J Rheumatol. 1994; 21: 2071-5.
44. Uesugi H, Ozaki S, Sobajima J, et al. Prevalence and characterization of novel pANCA, antibodies to the high mobility group non-histone chromosomal proteins HMG1 and HMG2, in systemic rheumatic diseases. J Rheumatol. 1998; 25: 703-9.
45. Yoshizaki A, Komura K, Iwata Y, et al. Clinical significance of serum HMGB-1 and sRAGE levels in systemic sclerosis: association with disease severity. J Clin Immunol. 2009; 29: 180-9.
46. Maugeri N, Franchini S, Campana L, et al. Circulating platelets as a source of the damage-associated molecular pattern HMGB1 in patients with systemic sclerosis. Autoimmunity. 2012; 45: 584-7.
47. Maugeri N, Rovere-Querini P, Baldini M, et al. Oxidative stress elicits platelet/leukocyte inflammatory interactions via HMGB1: a candidate for microvessel injury in sytemic sclerosis. Antioxid Redox Signal. 2014; 20: 1060-74.
48. Popescu LM, Faussone-Pellegrini MS. TELOCYTES-a case of serendipity: the winding way from Interstitial Cells of Cajal (ICC), via Interstitial Cajal-Like Cells (ICLC) to TELOCYTES. J Cell Mol Med. 2010; 14: 729-40.
49. Ceafalan L, Gherghiceanu M, Popescu LM, et al. Telocytes in human skin-are they involved in skin regeneration? J Cell Mol Med. 2012; 16: 1405-20.
50. Dardenne AD, Wulff BC, Wilgus TA. The alarmin HMGB-1 influences healing outcomes in fetal skin wounds. Wound Repair Regen. 2013; 21: 282-91.
51. Bani D, Formigli L, Gherghiceanu M, et al. Telocytes as supporting cells for myocardial tissue organization in developing and adult heart. J Cell Mol Med. 2010; 14: 2531-8.
52. Liou TG, Adler FR, Keogh RH, et al. Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis. PLoS ONE. 2012; 7: e42748.
53. Rowe SM, Jackson PL, Liu G, et al. Potential role of high-mobility group box 1 in cystic fibrosis airway disease. Am J Respir Crit Care Med. 2008; 178: 822-31.
54. Entezari M, Weiss DJ, Sitapara R, et al. Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas aeruginosa pneumonia in cystic fibrosis. Mol Med. 2012; 18: 477-85.
55. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007; 11: 1031-51.
56. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005; 115: 209-18.
57. Iredale JP. Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007; 117: 539-48.
58. Yao Q, Lin Y, Li X, et al. Curcumin ameliorates intrahepatic angiogenesis and capillarization of the sinusoids in carbon tetrachloride-induced rat liver fibrosis. Toxicol Lett. 2013; 222: 72-82.
59. Kao YH, Jawan B, Goto S, et al. High-mobility group box 1 protein activates hepatic stellate cells in vitro. Transplant Proc. 2008; 40: 2704-5.
60. Albayrak A, Uyanik MH, Cerrah S, et al. Is HMGB1 a new indirect marker for revealing fibrosis in chronic hepatitis and a new therapeutic target in treatment? Viral Immunol. 2010; 23: 633-8.
61. Ge WS, Wu JX, Fan JG, et al. Inhibition of high-mobility group box 1 expression by siRNA in rat hepatic stellate cells. World J Gastroenterol. 2011; 17: 4090-8.
62. Tu CT, Yao QY, Xu BL, et al. Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression. Food Chem Toxicol. 2012; 50: 3343-51.
63. Wang FP, Li L, Li J, et al. High mobility group box-1 promotes the proliferation and migration of hepatic stellate cells via TLR4-dependent signal pathways of PI3K/Akt and JNK. PLoS ONE. 2013; 8: e64373.
64. Leemans JC, Butter LM, Pulskens WP, et al. The role of Toll-like receptor 2 in inflammation and fibrosis during progressive renal injury. PLoS ONE. 2009; 4: e5704.
65. Boor P, Casper S, Celec P, et al. Renal, vascular and cardiac fibrosis in rats exposed to passive smoking and industrial dust fibre amosite. J Cell Mol Med. 2009; 13: 4484-91.
66. Chuang PY, Menon MC, He JC. Molecular targets for treatment of kidney fibrosis. J Mol Med (Berl). 2013; 91: 549-59.
67. Lynch J, Nolan S, Slattery C, et al. High-mobility group box protein 1: a novel mediator of inflammatory-induced renal epithelial-mesenchymal transition. Am J Nephrol. 2010; 32: 590-602.
68. Liu CP, Kuo MS, Wu BN, et al. NO-releasing xanthine KMUP-1 bonded by simvastatin attenuates bleomycin-induced lung inflammation and delayed fibrosis. Pulm Pharmacol Ther. 2014; 27: 17-28.
69. Tang N, Zhao Y, Feng R, et al. Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts. J Cell Mol Med. 2014; 18: 156-69.
70. He M, Kubo H, Ishizawa K, et al. The role of the receptor for advanced glycation end-products in lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007; 293: L1427-36.
71. Englert JM, Kliment CR, Ramsgaard L, et al. Paradoxical function for the receptor for advanced glycation end products in mouse models of pulmonary fibrosis. Int J Clin Exp Pathol. 2011; 4: 241-54.
72. Hamada N, Maeyama T, Kawaguchi T, et al. The role of high mobility group box1 in pulmonary fibrosis. Am J Respir Cell Mol Biol. 2008; 39: 440-7.
73. Pittet JF, Koh H, Fang X, et al. HMGB1 accelerates alveolar epithelial repair via an IL-1β- and αvβ6 integrin-dependent activation of TGF-β1. PLoS ONE. 2013; 8: e63907.
74. Ebina M, Taniguchi H, Miyasho T, et al. Gradual increase of high mobility group protein b1 in the lungs after the onset of acute exacerbation of idiopathic pulmonary fibrosis. Pulm Med. 2011; 2011: 916486.
75. Abe S, Hayashi H, Seo Y, et al. Reduction in serum high mobility group box-1 level by polymyxin B-immobilized fiber column in patients with idiopathic pulmonary fibrosis with acute exacerbation. Blood Purif. 2011; 32: 310-6.
76. Elnakish MT, Kuppusamy P, Khan M. Stem cell transplantation as a therapy for cardiac fibrosis. J Pathol. 2013; 229: 347-54.
77. Kim YS, Kang WS, Kwon JS, et al. Protective role of 5-azacytidine on myocardial infarction is associated with modulation of macrophage phenotype and inhibition of fibrosis. J Cell Mol Med. 2014; 18: 1018-27.
78. Wang WK, Wang B, Lu QH, et al. Inhibition of high-mobility group box 1 improves myocardial fibrosis and dysfunction in diabetic cardiomyopathy. Int J Cardiol. 2014; 172: 202-12.
79. Chen J, Han Q, Pei D. EMT and MET as paradigms for cell fate switching. J Mol Cell Biol. 2012; 4: 66-9.